Imunon Management
Management criteria checks 2/4
Imunon's CEO is Stacy Lindborg, appointed in May 2024, has a tenure of 4.92 years. total yearly compensation is $1.03M, comprised of 55.2% salary and 44.8% bonuses, including company stock and options. directly owns 0.097% of the company’s shares, worth $9.89K. The average tenure of the management team and the board of directors is 1.6 years and 7.8 years respectively.
Key information
Stacy Lindborg
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 55.19% |
| CEO tenure | 2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.6yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Frontline Ovarian Cancer Trial Success Will Transform Long Term Potential For This IL 12 Therapy
Catalysts About Imunon Imunon is a clinical stage biotechnology company focused on developing IMNN-001, an IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?
Phase III Ovarian Cancer Trial And IL-12 Focus Will Reshape This Long-Term Thesis
Catalysts About Imunon Imunon is a clinical stage biotechnology company developing IMNN-001, an intraperitoneal IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$15m |
| Dec 31 2025 | US$1m | US$568k | -US$14m |
| Sep 30 2025 | n/a | n/a | -US$14m |
| Jun 30 2025 | n/a | n/a | -US$16m |
| Mar 31 2025 | n/a | n/a | -US$18m |
| Dec 31 2024 | US$1m | US$342k | -US$19m |
| Sep 30 2024 | n/a | n/a | -US$19m |
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$19m |
| Dec 31 2023 | US$44k | n/a | -US$20m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$55k | n/a | -US$36m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$26m |
| Dec 31 2021 | US$63k | n/a | -US$21m |
Compensation vs Market: Stacy's total compensation ($USD1.03M) is above average for companies of similar size in the US market ($USD627.70K).
Compensation vs Earnings: Stacy's compensation has been consistent with company performance over the past year.
CEO
Stacy Lindborg (54 yo)
Dr. Stacy R. Lindborg, Ph D., was Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since January 2023 until May 09, 2024 and serves as its Director since May 09, 2024. Dr. Lindborg joined th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 19.3yrs | US$605.90k | 0.14% $ 14.6k | |
| President | 2yrs | US$1.03m | 0.097% $ 9.9k | |
| Chief Medical Officer | 1.3yrs | US$636.33k | no data | |
| Interim Chief Financial Officer | less than a year | US$807.99k | 0.00066% $ 67.0 | |
| General Counsel & Corporate Secretary | 1.6yrs | no data | 0% $ 0 | |
| Senior Vice President of Strategic Operations | 1.6yrs | no data | no data |
Experienced Management: IMNN's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 19.3yrs | US$605.90k | 0.14% $ 14.6k | |
| President | 4.9yrs | US$1.03m | 0.097% $ 9.9k | |
| Independent Director | 10.4yrs | US$61.49k | 0.11% $ 11.2k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 3.7yrs | US$85.97k | 0.097% $ 9.9k | |
| Independent Director | 14.8yrs | US$84.04k | 0.12% $ 11.8k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of the Advisory Board | 5.3yrs | no data | no data |
Experienced Board: IMNN's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/15 22:52 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Imunon, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |